Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA's human medicines commi
The US Food and Drug Administration (FDA) has approved a new cell-based therapy for blood cancer, developed by Janssen and China's Legend Biotech to treat multiple myeloma.
Gilead Sciences has taken a big step towards positioning its CAR-T therapy Yescarta as an option for previously-untreated large B cell lymphoma (LBCL) with updated results from the ZUMA-12
Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus Therapeutics, to help it take acute lymphoblastic leukaemia (ALL) CAR-T therapy ob
Gilead Sciences' Kite Pharma has won a key victory on appeal in its long-running dispute with Bristol Myers Squibb over patents relating to CAR-T therapies, overturning a $1.2 billion fine